2021
Difference in HIV testing behavior by injection status, among users of illicit drugs
Gordon KS, Chiasson MA, Hoover DR, Martins SS, Wilson PA, Lewis CF. Difference in HIV testing behavior by injection status, among users of illicit drugs. AIDS Care 2021, 34: 776-783. PMID: 33856945, DOI: 10.1080/09540121.2021.1913716.Peer-Reviewed Original ResearchConceptsHIV testing behaviorsHIV testingTesting behaviorSex networksHuman immunodeficiency virus (HIV) infectionInjection statusNon-injected drugsImmunodeficiency virus infectionIllicit drugsCross-sectional designEmotional supportHIV prevalenceSocial network characteristicsHIV epidemicInjected drugsVirus infectionCondomless sexHeroin useAnalytic sampleNegative binomial regression modelsBinomial regression modelsDrugsPWNDRegression modelsStatus
2012
Patient-Reported Symptoms on the Antiretroviral Regimen Efavirenz/Emtricitabine/Tenofovir
Edelman EJ, Gordon K, Rodriguez-Barradas MC, Justice F. Patient-Reported Symptoms on the Antiretroviral Regimen Efavirenz/Emtricitabine/Tenofovir. AIDS Patient Care And STDs 2012, 26: 312-319. PMID: 22612469, PMCID: PMC3412583, DOI: 10.1089/apc.2012.0044.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAlkynesAnti-HIV AgentsBenzoxazinesCohort StudiesCross-Sectional StudiesCyclopropanesDeoxycytidineDrug Therapy, CombinationEmtricitabineFemaleHealth StatusHIV InfectionsHumansMaleMiddle AgedOrganophosphonatesQuality of LifeSeverity of Illness IndexTenofovirTreatment OutcomeVeteransConceptsEFV/FTC/TDFCombination antiretroviral therapyFTC/TDFHealth-related qualityTDF useSymptom experienceEfavirenz/emtricitabine/tenofovirVeterans Aging Cohort StudyPatient-reported symptomsAging Cohort StudyEmtricitabine/tenofovirCross-sectional analysisAntiretroviral therapyCohort studyMost patientsPatient tolerabilitySymptom burdenTreatment characteristicsPatientsDisease severityAnalytic sampleTenofovirSymptomsTDFAssociation